{
    "clinical_study": {
        "@rank": "87469", 
        "arm_group": {
            "arm_group_label": "IPL Treatment", 
            "arm_group_type": "Experimental", 
            "description": "10 allogeneic stem cell transplant/GVHD subjects with severe dry eye symptoms from ocular rosacea unresponsive to conventional management will be treated with monthly over 4 months with IPL and meibomian gland expression"
        }, 
        "brief_summary": {
            "textblock": "Is Intense Pulsed Light (IPL) treatment and eyelid meibomian gland manual expression safe\n      and effective for allogeneic stem cell transplant patients with ocular rosacea in the\n      setting of quiescent graft-versus-host disease?"
        }, 
        "brief_title": "Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular GVHD", 
        "condition": [
            "GVHD", 
            "Ocular Rosacea"
        ], 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ocular rosacea with inactive GVHD\n\n        Exclusion Criteria:\n\n          -  Active GVHD\n\n          -  Facial laser treatment\n\n          -  Accutane exposure\n\n          -  Inability to wear sun protection factor (SPF) 30 sunscreen and avoid sun exposure\n\n          -  Inability to meet study requirements"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066051", 
            "org_study_id": "13-003814"
        }, 
        "intervention": {
            "arm_group_label": "IPL Treatment", 
            "description": "Intense Pulsed Light (IPL) treatment", 
            "intervention_name": "IPL", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "last_name": "Joanne Shen, MD", 
                "phone": "480-301-8000"
            }, 
            "facility": {
                "address": {
                    "city": "Scottsdale", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85259"
                }, 
                "name": "Mayo Clinic Arizona"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD)", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Joanne Shen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Identify 10 allogeneic stem cell transplant/GVHD subjects with severe dry eye symptoms from ocular rosacea unresponsive to conventional management and treat with monthly IPL and meibomian gland expression over 4 months with an 8 month monitoring period", 
            "measure": "Number of participants who respond to IPL", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066051"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Joanne F. Shen, M.D.", 
            "investigator_title": "Assistant Professor of Ophthalmology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "monitor safety during treatment", 
            "measure": "Number of participants who experience adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}